

LANKA 202

WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit Ministry of Health, Nutrition & Indigenous Medicine 231, de Saram Place, Colombo 01000, Sri Lanka Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk Web: http://www.epid.gov.lk

Vol. 49 No. 18

Influenza Part II

This is the secound of a series of 3 articles


Presentation

The presentation of influenza virus infection varies with those who have preexisting immunity or who have received the vaccine having milder symptoms.

The onset of illness can occur suddenly over a day, or it can progress more slowly over several days. Typical signs and symptoms include the following:

- Cough (can be severe and can last 2 or more weeks) and other respiratory symptoms (non-productive cough, cough-related pleuritic chest pain, and dyspnea)
- Fever (100°- 104°F)
- Sore throat (may be severe and may last 3 to 5 days)
- Myalgia (common and range from mild to severe)
- Headache (Frontal or retro-orbital headache is common and is usually severe)
- Nasal discharge (Rhinitis)
- Weakness and severe fatigue (may prevent patients from performing their normal activities, need additional sleep, may be bedridden if severe)
 Tachycardia
- Ocular symptoms (red, watery eyes, photophobia, burning sensations, or pain upon motion)

Most people recover from fever and other symptoms within a week without requiring medical attention. But influenza can cause severe illness, hospitalization or death, especially in people at high risk. All pregnant women presenting with symptoms should be referred to a centre with specialist care within the first 24 hours.



Diagnosis

The majority of cases of human influenza are clinically diagnosed. However, during periods of low influenza activity and outside of epidemics situations, the infection of other respiratory viruses e.g. rhinovirus, respiratory syncytial virus, parainfluenza and adenovirus can also present as Influ-

Contents	Page
1. Influenza Part II	1
2. Summary of selected notifiable diseases reported $(23^{th} - 29^{th} \text{ Apr } 2022)$	3
3. Surveillance of vaccine preventable diseases & AFP (23th – 29th Apr 2022)	4

30th- 06th May 2022

COMPLICATIONS

WER Sri Lanka - Vol. 49 No. 18

enza-like Illness (ILI) which makes the clinical differentiation of influenza from other pathogens difficult.

The collection of appropriate respiratory samples and the application of a laboratory diagnostic test is required to establish a definitive diagnosis. Proper collection, storage and transport of respiratory specimens are the essential first steps for laboratory detection of influenza virus infections. Laboratory confirmation of influenza virus from the throat, nasal and nasopharyngeal secretions or tracheal aspirate or washings is commonly performed using direct antigen detection, virus isolation, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR). Guidance on laboratory techniques is published and updated by the World Health Organization.

Rapid influenza diagnostic tests (RIDTs) are used in clinical settings, but they have lower sensitivity compared to RT-PCR methods and their reliability depends largely on the conditions under which they are used. Serologic testing can also confirm the diagnosis but is rarely used in a clinical setting.

Treatment

Patients with uncomplicated seasonal influenza:

Patients that are not from a high risk-group should be managed with **symptomatic treatment** and are advised, if symptomatic, to stay home to minimize the risk of infecting others in the community. Treatment focuses on relieving symptoms of influenza such as fever. Patients should monitor themselves to detect if their condition deteriorates and seek medical attention Patients that are known to be in a group at high risk for developing a severe or complicated illness, should be treated with antivirals in addition to symptomatic treatment as soon as possible.

Patients with severe or progressive clinical illness associated with suspected or confirmed influenza virus infection (i.e. clinical syndromes of pneumonia, sepsis or exacerbation of chronic underlying diseases) should be treated with antiviral drugs as soon as possible.

• Neuraminidase inhibitors (i.e. oseltamivir) should be prescribed as soon as possible (ideally, within 48 hours following symptom onset) to maximize therapeutic benefits. Administration of the drug should also be considered in patients presenting later in the course of illness.

• Treatment is recommended for a minimum of 5 days but can be extended until there is satisfactory clinical improvement.

• Corticosteroids should not be used routinely unless indicated for other reasons (eg: asthma and other specific conditions); as it has been associated with prolonged viral clearance and immunosuppression leading to bacterial or fungal superinfection.

All currently circulating influenza viruses are resistant to

adamantane antiviral drugs (such as amantadine and rimantadine), and these are therefore not recommended for monotherapy.

The World Health Organizations Global Influenza Surveillance and Response System (GISRS) monitors **resistance to antivirals** among circulating influenza viruses to provide timely guidance for antiviral use in clinical management and potential chemoprophylaxis.

Prevention

To prevent transmission, public health management measures include personal protective measures like:

- Regular hand washing with proper drying of the hands
- Good respiratory hygiene covering mouth and nose when coughing or sneezing, using tissues and disposing of them correctly
- Early self-isolation of those feeling unwell, feverish and having other symptoms of influenza
- Avoiding close contact with sick people
- Avoiding touching one's eyes, nose or mouth
- The most effective way to prevent the disease is vaccination. Inactivated influenza viral vaccines matching the currently circulating strains are produced annually and recommended especially for those at high risk (among the elderly, influenza vaccination may be less effective in preventing illness but reduces the severity of disease and incidence of complications and deaths). Immunity from vaccination decreases over time so annual vaccination is recommended to protect against influenza.

There are two types of vaccines available inactivated and live attenuated. In Sri Lanka inactivated trivalent vaccine is available in the private sector.

The World Health Organization recommends annual vaccination for:

- pregnant women at any stage of pregnancy
- children aged between 6 months to 5 years
- elderly individuals (aged more than 65 years)
- individuals with chronic medical conditions
- health-care workers.

Compiled by :

Dr T. D. Bandara MBBS (Colombo), MSc. Community Medicine Medical Officer – Epidemiology Unit

WER Sri Lanka - Vol. 49 No . 18

30th-06th May 2022

Table 1: Selected notifiable diseases reported by Medical Officers of Health 23rd- 29th Apr 2022 (17th Week)																													
	*5	66	72	100	96	100	100	100	100	100	88	100	81	79	100	100	100	92	100	92	87	88	100	100	95	100	100	95	
WRCD	*	10	ŝ	4	9	17	10	2	13	20	52	32	23	7	25	32	œ	19	ы	Ħ	9	11	œ	9	2	ы	25	13	
			7	0	4	145	0	0	178	107	0		0	0			7	0	179	4	178	144	7	49	84	10	0	1107	
Leishmania-	AB	0	0	0	2	m	0	0	14	ъ	0	0	0	0	0	0	0	0	11	0		13	0	4	S	H	0	59	
	в	m	9	10	2	H	0	б	4	m	4	0	15	0	0	17	7	m	13	10	15	2	7	13	13	15	13	185	
Meningitis	A	0	2	0	0	0	0	0	0	0	0	0	÷	0	0		H	H		0		0	0	0	0	0	2	10	
xodua	В	12	10	25	21	8	6	25	14	11	51	m	e	ъ	m	ъ	25	11	29	m	19	4	20	23	28	34	17	418	
Chickenpox	A	2	0		m	0		0	0		7	0	0	0	0	0		m	2	0		0		2	2	9	ы	38	
_	В	0		1	0	0	0	0	0	0	m	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	9	
	A	0	0	0	0	0	0	0	0	0	H	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	H	
Hep-	в	2	m		4		0				4	0		0	0			4	0	0	2	0	48	20	11	2	0	10	
Viral Hep-	A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	Н	H	0	0	œ	
v	В	0	0	2	11	2	7	7	16	പ	349	7	2	1	4	0		m	13	m	14	0	18	11	7	7	H	491	
Typhus	A	0	0	0	0	0	0	H	1	0	9		0	0	H	0	0	0	0	0	0	0	m	0	0	0	0	13	
Leptospirosis	В	36	38	105	26	23	19	135	61	58	18	2	11	10	12	15	34	10	33	7	74	46	84	125	239	149	7	1377	
Lepto	A	2	2	ъ	H	4	0	6	ъ	m	H	0	0		0	0	2	m	2	0	0	4	ъ	20	14	14	m	10	
l Poi-	В	ъ	9	9	4	0	0	0	0	0	17	11	0	0	m	17	0	2	-	0	ъ	1	ъ	2	15	4	4	108	
Food	۲	0	0	0	0	0	0	0	0	0	H	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	H	
Encephaliti Enteric Fever Food Poi	в	0	0	1	0	0	0	0	0	0	38	0	0	2	2	0	0	H	0	0		0	0	4	H	H	0	51	
Ente	A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
phaliti	в	7	0	0	0	0	0	0	0	0	2	0	0	H	0	S		0		0	0	0	0	0	S	7	0	19	
Ence	A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	•	
Dysentery	8	7	4	4	4	0	∞	m	23	9	10	4		0	7	39	9	20	9	7	7	m	S	ъ	18	4	19	205	
r Dys	۲	0	0	0		0	0	0	0			0	0	0	0	7	0	0	0	2	0	0	0	0		0		5 14	
Dengue Fever	8	2647	2156	667	656	155	61	935	293	337	1324	55	146	43	30	487	56	597	1075	875	150	47	389	120	760	483	321	15195	
Den	◄	13	97	91	40	~	2	13	25	34	Ħ	ъ	Μ	0	Μ	40	m	73	14	21	~		9	~	46	29	39	98	
RDHS		Colombo	Gampaha	Kalutara	ƙandy	Matale	NuwaraEliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	/avuniya	Mullaitivu	Batticaloa	Ampara	Frincomalee	Kurunegala		Anuradhapur	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmune	SRILANKA	

Source: Weekly Returns of Communicable Diseases (esurvillance.epid.gov.lk). T=Timeliness refers to returns received on or before 29th Apr., 2022 Total number of reporting units 361 Number of reporting units data provided for the current week: 339 C**-Completeness

WER Sri Lanka - Vol. 48 No. 18

Table 2: Vaccine-Preventable Diseases & AFP

30th-06th May 2022

Disease		N	lo. of	Case	es b	y Pro	ovinc	Number of cases during current	Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date		
	w	С	S	N	Е	NW	NC	U	Sab	week in 2022	week in 2021	2022	2021	in 2022 & 2021
AFP*	00	01	01	00	00	00	00	00	00	02	00	31	19	63.1 %
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Mumps	00	01	00	00	00	00	00	00	00	01	03	14	37	- 62.1 %
Measles	00	00	00	00	00	00	00	00	00	00	02	10	08	25 %
Rubella	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Tetanus	01	00	00	00	00	00	00	00	00	01	01	04	02	100 %
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Japanese En- cephalitis	00	00	00	00	00	00	00	00	00	00	00	01	00	0 %
Whooping Cough	00	00	00	00	00	00	00	00	00	00	00	01	00	0 %
Tuberculosis	05	11	00	02	04	00	00	05	00	27	108	2446	2130	14.8 %

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam, AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS, Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis CRS** =Congenital Rubella Syndrome

NA = Not Available

Covid-19 Prevention & Control

For everyone's health & safety, maintain physical distance, often wash hands, wear a face mask and stay home.

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

ON STATE SERVICE

Dr. Samitha Ginige Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10